4/24
06:01 am
chrs
Coherus Oncology (CHRS) was upgraded by
Weiss Ratings from "sell (d+)" to "hold (c-)".
Low
Report
Coherus Oncology (CHRS) was upgraded by
Weiss Ratings from "sell (d+)" to "hold (c-)".
4/10
06:15 am
chrs
Coherus Oncology (CHRS) had its "sell (d+)" rating reaffirmed by
Weiss Ratings.
Low
Report
Coherus Oncology (CHRS) had its "sell (d+)" rating reaffirmed by
Weiss Ratings.
3/9
04:29 pm
chrs
Coherus BioSciences Non-GAAP EPS of -$0.34 misses by $0.03, revenue of $12.7M misses by $1.39M [Seeking Alpha]
Medium
Report
Coherus BioSciences Non-GAAP EPS of -$0.34 misses by $0.03, revenue of $12.7M misses by $1.39M [Seeking Alpha]
3/9
04:15 pm
chrs
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
3/2
09:30 am
chrs
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
Medium
Report
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
2/23
09:30 am
chrs
Coherus Oncology to Participate in Upcoming Investor Conferences
Low
Report
Coherus Oncology to Participate in Upcoming Investor Conferences
2/17
04:11 pm
chrs
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
Low
Report
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
2/12
09:18 pm
chrs
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
Medium
Report
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
2/12
04:05 pm
chrs
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
High
Report
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock